Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orkambi for Long QT Syndrome Type 2
NCT04581408Phase 2
Key facts
- Status
- Completed
- Start
- Jun 2021
- Primary completion
- Apr 2025
- Countries
- 1
- Sponsor
- Istituto Auxologico Italiano
- Modality
- Small Molecules
- Drugs
- lumacaftor
- Conditions
- Long QT syndrome type 2 (LQT2)
01
Overview
Phase 2, open-label, single-arm trial of lumacaftor in Long QT syndrome type 2 (LQT2), sponsored by Istituto Auxologico Italiano. Primary endpoint: QT interval. Started Jun 2021; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Orkambi
Lumacaftor/Ivacaftor treatment
03
Endpoints
Primary
QT interval
Beyond the preview
Go deeper on NCT04581408.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04581408.